Cornell’s Research Serves the Region and Beyond

Angiocrine Bioscience Inc. CTL

R&D: Biotechnology

  • Products:
  • VeraVec Endothelial Cells
  • Mouse Tissue Specific VeraVec Endothelial Cells
  • Amniotic Fluid-Derived Cells

Angiocrine Bioscience Inc. develops the VeraVec cellular platform for amplifying stem and progenitor cells, in both human and mouse models, by recapitulating the proliferative stimulation of the in vivo vascular niche in vitro. The expansion capacity is on an unprecedented scale when compared to any other competing technology, and it is achieved without costly mediate additives. This process meets the needs of a broad range of therapeutic, diagnostic, and research applications.

Cornell Connection

The company's foundational technology was created by a Weill Cornell Medicine professor and is licensed from Cornell University.